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Regulation of Macrophage-Derived Fibroblast Growth
Factor Release by Arachidonate Metabolites
Sem H. Phan, Bridget M. McGarry, Kathryn M. Loeffler, and Steven L. Kunkel
Department of Pathology, The University of Michigan Medical School, Ann Arbor
The macrophage is a source of many mediators with direct and Indirect fibrogenic
potential. In this study, release of macrophage-derived flbroblast growth factor (MDGF)
activity by murine peritoneal macrophages is examined with regard to its regulation by
arachidonate metabolites. Upon stimulation with 10 ,g/ml lIpopolysaccharide (LPS),
resident peritoneal macrophages from CBA/J mice released MDGF activity into media
rapidly, reaching maximal levels in approximately 1 h. Lysates of these stimulated cells
also revealed significantly increased cell-associated MDGF activity, composing 45% of
the total assayable activity. This activity, as assayed by radioactive thymidine incorpo-
ration by primary cultures of rat lung fibroblasts, was separable from Interleukin-1 (IL-i)
activity by reverse phase high performance liquid chromatography (HPLc). Furthermore,
purified murine IL-i had no MDGF activity in this assay system. This stimulated MDGF
release was enhanced by the cylooxygenase inhibitors indomethacin, Ibuprofen, and
aspirin at micromolar concentrations, but inhibited in a dose-dependent manner by
prostaglandin E2 (PGE2). On the other hand, nordihydrogualaretic acid (NDGA), a lipox-
ygenase Inhibitor was inhibitory at 0.1 and 0.4 M but not at 2.5 M. Zymosan-stimulated
macrophages also markedly increased MDGF release, albeit with a different time course
which was characterized by a delay of approximately 7 h before peak levels were
attained. Such stimulation, which Is known to cause increased Ilpoxygenase activity,
was also inhibited by 0.5 M NDGA. In contrast, the lipoxygenase pathway products
leukotrienes B4 (LTB4) and C4 (LTC4) stimulated MDGF release In a dose-dependent
(iO_b0_iO_8 M) manner, with LTc4 being more potent on a per unit dose basis. Stimula-
tion by LTC4 was Inhibited by the putative leukotriene receptor antagonist, FPL55712,
while LTD4 and LTE4 did not stimulate MDGF release, thus suggesting the mediation of
this effect by specific LTC4 receptors. These data suggest also that products of the
cyclooxygenase and lipoxygenase pathways are potentially important both as exoge-
nous (ie, derived from cells other than the macrophage Itself) and auto- or self-regula-
tors of macrophage MDGF release. This, in turn, implies that cyclooxygenase products
are antifibrogenic and important in maintaining or returning to the quiescent or normal
state, whereas the lipoxygenase products are profibrogenic and Important In Induction
of fibrosis or wound-healing and tissue repair. Any alteration in the balance between
these two pathways may result in either a desirable or a harmful outcome.
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INTRODUCTION
There is mounting evidence that the macrophage is an
important participant in the fibrogenic response. One of
the earliest hints comes from a study showing inhibition
of wound healing and scar formation in animals selec-
tively depleted of macrophages [18]. Since this study,
there have been multiple reports of macrophages as
sources of macrophage-derived fibroblast growth factor
(MDGF) and fibroblast collagen synthesis stimulatory
and fibroblast chemotactic activities [19,20,29,30,32].
Additionally, the macrophage is a major source of certain
arachidonate metabolites [4,17,26], which have well-
known fibrogenic modulating activities [1,8,10,16,20].
These metabolites, both endogenously and exogenously
(ie, from other cellular sources) derived, have been re-
ported also to modulate the production or release of
certain mediators by macrophages, such as interleukin 1
(IL-i) [6,7,17,25]. One of these metabolites, prostaglan-
din E2 (PGE2), inhibits IL-i release by lipopolysaccha-
ride (LPS)-stimulated macrophages and may represent
an important endogenous or autoregulator of IL-i re-
lease [17].
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Such modulation of macrophage mediator production
will ultimately have an impact on the fibrogenic re-
sponse, since many of these mediators, including the
arachidonate metabolites themselves, have direct effects
on fibroblast growth, movement, and protein metabolism
[1,8,10,16,19,20,29,30,32]. The modulation of MDGF
release by arachidonate metabolities has not been specif-
ically studied [24,31], although modulation of IL-l or
IL-i-like molecules with putative MDGF activity has
been reported [6, 17]. In preliminary studies, we have
reported that the cycbooxygenase inhibitor indomethacin
enhanced MDGF secretion by LPS-stimulated peritoneal
macrophages, while PGE was inhibitory [17]. In the
present study, we have extended these studies and also
examined the kinetics of MDGF release, the effects of
other cycbooxygenase and lipoxygenase inhibitors, and
leukotrienes on such stimulated release. Additionally,
data were presented showing that the measured MDGF
activity was distinct from IL-i.
MATERIALS AND METHODS
Reagents
LPS (from Escherichia coli, serotype 0111 :B4), nor-
dihydroguaiaretic acid (NDGA), indomethacin, aspirin
(acetylsalicylic acid), and acetaminophen were purchased
from Sigma Chemical Co. (St. Louis, MO). RPMI-l640,
Dulbecco’s modified Eagle’s medium (DMEM), penicil-
lin-streptomycin-fungizone stock solution, fetal calf
serum (FCS), and L-glutamine were obtained from
GIBCO (Grand Island, NY). Trypsin (1 :250) for isola-
tion and passaging cells was from Difco Laboratories
(Detroit, MI). Ibuprofen was obtained from the Upjohn
Co. (Kalamazoo, MI). BW755c was from Wellcome Re-
search Laboratories (Beckenham, England). PGE2 was a
gift from Pfizer Central Research (Groton, CT). Dr. J.
Rokach (Merck Frosst Laboratories, Quebec, Canada)
kindly provided the LTB4 and LTC4. [Methyl-
3H]thymidine (6.7 ci/mmol) was purchased from New
England Nuclear (Boston, MA). All other reagents were
of analytical reagent grade or better.
Cells
Resident mouse peritoneal macrophages were obtained
by lavaging the peritoneal cavities of female CBA/J mice
(The Jackson Laboratories, Bar Harbor, ME) with sterile
RPMI exactly as previously described [17]. Adherent
cells were then incubated in serum-free RPM! containing
10 tg/mi LPS with or without various arachidonate me-
tabolities or inhibitors of cycbooxygenase or lipoxygenase
pathways [17]. Except for the time course studies, the
incubation continued for 16-18 h (overnight). Condi-
tioned media were then harvested, and the volume was
determined. After counting of the adherent cells, the
media were then adjusted to the equivalent of l0 adher-
ent cells/mi prior to filter sterilization and storage at
-20#{176}Cuntil ready for mediator assay. When zymosan
was used, the media were centrifuged to remove the
zymosan prior to filter sterilization. Where indicated,
macrophage lysates were prepared by repeated freezing
and thawing of the adherent cells after collection of
conditioned media, washing and resuspension in fresh
RPM! [17]. The supernatant after removal of cellular
debris by centrifugation was filter sterilized and stored
frozen until assay, and referred to as the cell-associated
fraction or lysate.
Rat lung fibroblasts were isolated from specific patho-
gen-free male Fisher 344 rats (Charles River, Portage,
MI) by trypsinization of fresh lung mince as previously
described [22]. Cells were maintained in DMEM con-
taming 10% FCS. Only cells from passages 3-15 were
used for MDGF assay [17, 22]. In control experiments,
these rat lung fibroblasts did not differ significantly from
murine lung fibroblasts in their responsiveness to mac-
rophage-conditioned media (data not shown). Since the
rat cells were easier to maintain in culture, all experi-
ments were undertaken with these cells.
Macrophage-conditioned media and lysates at 10% fi-
nal concentrations were assayed for MDGF activity as
previously described [17]. Data were expressed as cpm
incorporated per microtiter well. Quiescent untreated
control fibroblasts usually incorporated 200-700 cpm/
well while the positive controls (in the presence of 10%
FCS) usually incorporated 7,000-10,000 cpm/well.
Chromatography
Conditioned media from LPS-stimulated macrophages
were concentrated tenfold prior to analysis by reverse
phase high performance liquid chromatography (HPLC).
The instrumentation consisted of a Varian 5560 chroma-
tograph equipped with a UV-200 UV-visible variable
wavelength detector and a model 402 data system (Varian
Instruments, Palo Alto, CA). A Supelco (Bellefonte, PA)
LC-304 column was used for this analysis. This column
(4.6 mm x 15 cm) contained 30-sm-diameter pore size
resin with a C4 bonded phase. The column was eluted
with a linear gradient of 10-50% B over 40 minutes,
with solvent A composed of 0.05 M ammonium acetate
(pH 6.8), in H2O and solvent B composed of the same
buffer composition, but in 50% CH3CN (in H2O). The
column temperature was maintained at 35#{176}C,and the
flow rate was 1 mI/mm. The effluent was detected at 230
nm and 1 ml fractions were collected, dried by vacuum
centrifugation (Speed Vac, Savant Instruments, Hicks-
ville, NY), and subsequently assayed for MDGF and IL-
1 activities after resuspension in RPM!.
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Fig. i . StImulation of MDGF activity by LPS. Resident murine
peritoneal macrophages were Incubated for 16 h in the pres-
ence (LPS) or absence (NONE) of 10 ,g/ml LPS. ondItloned
media were then separated from the adherent cell layer, and
tested for MDGF activity as described In Materials and Meth-
ods. The cell layer was frozen and thawed to lyse the cells, and
the supernate obtained after centrifugatlon was also assayed
for MDGF activity (lysate fraction). Control refers to cpm incor-
porated In the presence of DMEM containing 0.4% FCS. Data
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FIg. 2. Reverse phase HPLC separation of MDGF from IL-i.
LPS-stimulated macrophage conditioned media were concen-
trated tenfold, and Injected onto a c4 reverse phase column
(see Materials and Methods for details). The effluent was mon-
itored at 230 nm and i-mi fractions were collected, dried, and
assayed for MDGF and IL-i activities.
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lnterleukln-1 Assay
CONTROL ( DMEM 0.4) _____ This was done exactly as described previously [17],
using a modification of the method of Mizel et al [21].
NONE-mdia #{149}
Statistical Analysis
NONE-iysate Student’s t-test was used for comparing means of ex-




LPS is a potent stimulator of macrophage mediator
release This effect was also observed in terms of MDGF
activity: 10 pg/mi of LPS caused a 2-5-fold increase in
the MDGF activity of macrophage-conditioned media
when compared to control media of unstimulated cells.
A typical result is shown in Figure 1, wherein an approx-
imate fivefold stimulation was seen. This stimulated ac-
tivity was also found in the lysates of LPS-stimulated
macrophages, although the degree of stimulation was
only slightly greater than twofold that of the lysates from
unstimulated cells (Fig. 1). In terms of activity, the lysate
contained approximately 45 % of the total assayable activ-
ity (lysate plus media). Addition of the same dose of LPS
directly into the MDGF assay failed to affect fibroblast
thymidine incorporation (data not shown).
Since LPS-stimulated macrophages also release IL-i
[13, 17, 2 1], and IL-i has been reported to have FGF-like
activity [27], the question arose as to whether this MDGF
activity could be due to IL-i. In an attempt to clarify this
issue, concentrated conditioned media from LPS-stimu-
lated macrophages were fractionated by reverse phase
HPLC. The resulting chromatogram showed that MDGF
activity with a retention time centered around 10 mm was
clearly separable from fractions exhibiting IL-i activity
with a retention time of approximately 19 mm (Fig. 2).
The IL-i-containing fractions showed no detectable
MDGF activity, except in the presence of high concentra-
tions of serum ( > 5 %), while the MDGF positive peak
was inactive in the IL-i assay. Thus, this LPS-induced
MDGF activity was physically distinct from IL-i, as
have also been shown by others [3,9,11]. Finally, Table
1 shows the inability of purified murine IL-i (a gift of
Dr. M. Kluger, Department of Physiology, University of
Michigan) [21] to significantly stimulate thymidine incor-
poration by fibroblasts in the MDGF assay.
The time course of this LPS stimulation of MDGF
release was rapid, as shown in Figure 3. Maximal MDGF
activity in conditioned media was observed within the
first hour after addition of LPS. Simultaneous addition of
the cycbooxygenase inhibitor indomethacin with the LPS
caused an approximately 50% increase in MDGF activity
release above that of LPS alone (Fig. 3). To examine this
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TABLE 1. Effect o f Murine IL-i on Fibroblasts
Treatment Dose MDFG activitya
None - 398 ± 42










aActivity assayed as described in Materials and Methods, and expressed as mean cpm/
well ± SE (N =6).
bThis represents conditioned media of LPS-stimulated macrophages.
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Fig. 3. Kinetics of LPS-Induced MDGF release. Macrophages
were incubated In the presence of iOjLg/ml LPS, with (#{149}-#{149})or
without (#{149}-#{149})i M indomethacin. At the indicated times, after
addition of LPS, conditioned media were collected and assayed
for MDGF activity. Data presented as mean ± SE, N = 6.
INDOMETHACIN (uM)
Fig. 4. Dose-response curve for indomethacin. indomethacin
were added at the indicated doses to LPS (iO g/ml) stimulated
macrophages. After 16 h, the conditioned media were collected
and assayed for MDGF activity. Data expressed as mean ± SE,
N = 6.
was examined along with the effects of other arachidon-
ate metabolic inhibitors.
The Role of Cyclooxygenase Metabolites
The stimulatory effects of indomethacin were dose-
dependent, saturating at doses greater than S x i07M
(Fig. 4). Addition of these doses of indomethacin directly
into the MDGF assay or into macrophage-conditioned
media did not affect significantly the rate of thymidine
incorporation by the target fibroblasts (Table 2). Thus,
any effect that was observed was due to the effect of
indomethacin on MDGF production and/or release. In
order to examine if this stimulatory effect was shared by
other cyclooxygenase inhibitors, several of them were
tested for their effects on LPS-induced MDGF release.
Figure 5A shows that this property was shared by ibupro-
fen and aspirin, although the effects were smaller on a
per unit dose basis. Acetaminophen also stimulated
MDGF release, although it is not known as a cyclooxy-
genase inhibitor [17]. On the other hand, piroxicam and
the lipoxygenase inhibitor BW755c were ineffective in
influencing LPS-induced MDGF release. These results
do not seem to correlate with the abilities of these agents
to inhibit PGEI production as previously reported [17],
although Figure SB confirms the dose-dependent inhibi-
tory effect of PGE on LPS-induced MDGF release [17].
PGE2 at these dilutions (  1 x l07)did not significantly
inhibit the fibroblasts in the MDGF assay (Table 2). The
data would thus suggest the possibility that these agents
may exert their effect via multiple mechanisms in addi-
tion to the inhibition of the cyclooxygenase pathway,
unlike the situation with IL-i release, wherein stimula-
tion of its release by these inhibitors correlated with the
inhibition of macrophage PGE production [i7].
The Role of Lipoxygenase Metabolites
In contrast to the stimulatory effects of the cycbooxy-
genase inhibitors, the lipoxygenase inhibitor NDGA in-
hibited LPS-induced MDGF release in a dose-dependent
manner (Fig. 6). The inhibitory effect, however, was not
seen at 2.5 M, the highest dose tested. This was possi-
bly due to concomitant cyclooxygenase inhibition by high
doses of NDGA, as has been previously reported [5].
The inhibitory effect of lipoxygenase inhibition on MDGF
release was also suggested by the BW755c data (Fig.
SA), showing slight inhibition of MDGF release by this
inhibitor of LTC4 production [5]. NDGA added directly
to the fibroblasts did not affect thymidine incorporation
significantly (Table 2).
ip<0.01
0 1000 2000 3000 4000
MDGF ACTIVITY (cpm/w.II)
_____________ _________________________ Since LPS does not cause significant stimulation of the
_____________ production of lipoxygenase metabolites [14, 17], this
NDGA effect was further examined using zymosan, an
agent known to cause stimulation of the lipoxygenase
IBUPROFEN I P< 0.05 pathway [14, 17]. Addition of zymosan also caused in-
ASPIRIN I p< 0.02 creased production of MDGF activity, but with a differ-
PIROXICAM  NS ent kinetics compared to LPS . Instead of almost
BW755c INS instantaneous release as seen with LPS (Fig. 3), a lag
ACETAMINOPHEN I p< 0.005 phase of approximately 6 h was observed with zymosan
__________________________ stimulation before maximal release was attained at time
points greater than 9 h (Fig. 7) . The inhibitory effects of
A NDGA (5 x l0 M) was again observed, thus suggest-
___________________________ ing that inhibition was occurring at a step or steps com-
mon to macrophage activation by these two different
agents. In view of the antiipoxygenase activity of NDGA,
LPS I several lipoxygenase pathway products were tested for
their ability to modulate, especially stimulate, MDGF
release by macrophages.
LPS + 0.lpM PGE2 I Addition of LTB4 and LTC4 to macrophage cultures,
caused a dose-dependent increase in MDGF release (Fig.
______ 8). LTC4 stimulation was significantly greater than LTB4
LPS + 1.OpM POE2  stimulation on a per unit dose basis, although their half-
maximal effective doses (ED5#{176})were similar at approxi-
-I I  I I I I mately S x 109M. Addition of these leukotrienes di-
0 1000 2000 3000 4000 rectly to fibroblast cultures at these dilutions had no
B MDGF (cpmlw.II) significant effect on thymidine incorporation (data not
Fig. 5. Effects of cyclooxygenase Inhibitors and PGE2. A: In- shown). These effects were thus the result of actual
hibitors (I M) were added to LPS (10 g/ml) stimulated mac- increase in MDGF release by the macrophages. The
rophage cultures. After 16 h conditioned media were collected stimulatory effect of LTC4 was blocked by the putative
and assayed for MDGF. Data were presented as means ± SE
(N = 6, except for Indomethacin, where N = 5). p value mdi- sulfidopeptide leukotnene receptor antagonist FPL5S712,
cated the results of comparing their mean values to the LPS suggesting that the effect was mediated by an LTC4
(no Inhibitor) control mean value, by Student’s t-test. NS refers receptor on the macrophage. Although FPL55712 has
to p  0.05. B: PGE2 was added to LPS-stlmuiated macro- greater specificity for LTD4, at least in guinea pig trachea
phages at the indicated concentrations, and the conditioned [28], this leukotriene as well as LTE4 did not stimulate
media were harvested to assay for MDGF activity. Data repro- MDGF release at comparable doses (data not shown).












TABLE 2. Effects of Indomet hacin, NDGA, and PGE2 o n MDGF Assay
Treatment Dose [3H]Thymidine incorporationa
None - 346 ± 69
MDGFh 10% 2,100 ± 193
Indomethacinc 1 x 107M 511 ± 103
Indomethacin 2.5 x 107M 623 ± 122
MDGF + Indomethacind 10% 2,351 ± 271
NDGAC 1 x 107M 392 ± 101
NDGA 2.5 x 107M 569 ± 92
MDGF + NDGA 10% 2,009 ± 215
PGE2 l07M 403 ± 103
MDFG + PGE, 10% 1,603 ± 100
MDGF assay was done as described in Materials and Methods, and results are expressed as mean cpm/
well ± SE (N = 3).
bThis represents LPS-stimulated macrophage conditioned media.
cAdded directly to the fibroblasts, and incubated as for the standard MDGF assay, but without addition
of conditioned media.
dThis represents macrophage conditional media as in footnote b above, into which l06M indomethacin,
NDGA, or PGE2 had been added just prior to the MDGF assay, resulting in a final concentration of
107M in the MDGF assay for each of these compounds.
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These data complemented the NDGA data and con-
4000 firmed the possibility that lipoxygenase pathway prod-
2 ucts, either endogenously produced by the macrophage,
or exogenously introduced, are stimulatory to MDGF
I





4 Arachidonate metabolites appear to have complex bi-
IL.
C., directional effects on macrophage mediator production
0 2000
 [6,7, 17, 24, 25 ,31]. This state of affairs appear to extend
 ‘ , ‘ , . , also to MDGF release. LPS caused a rapid increase in
0 0.5 1.0 1.5 2.0 2.5 MDGF release which was further stimulated in a dose-
NDGA (uM) dependent manner by the cyclooxygenase inhibitor indo-
Fig. 6. Dose-response curve for NDGA. The experimental pro- methacin. This secreted MDGF activity was physically
tocol was identical with that described In the legend to Figure distinct from IL-I, as indicated by the ability of reverse
4, except NDGA at the Indicated doses was added, instead of phase HPLC to separate these two activities. That this
indomethacin. Data represent means ± SE (N = 6). MDGF was different from IL-i was also supported by
the inability of purified murine IL-i to significantly slim-
ulate thymidine incorporation by fibroblasts used in the
- MDGF assay. Further support was also provided by
; studies from other laboratories [3, 9, 1 1] , and by the dif-
S
ference in the effectiveness of various cyclooxygenase
. inhibitors to modulate IL-i [17] versus MDGF release as
,. discussed below.
 The stimulatory property of indomethacin was also
U shared by ibuprofen and aspirin, but not by piroxicam4
 and BW7SSc. In previous studies, we have shown that0
0
, indomethacin, ibuprofen, and piroxicam inhibited PGE2
6 #{149}10 12 14 16 18 production by these macrophages [17], while asprin was
TIME (hours) inhibitory at much higher doses [17]. If the mechanism
Fig. 7. KinetIcs of zymosan-induced MDGF release. Experi- of the stimulation is due to decreased production of PGE,
mental protocol was Identical with that described In legend to then all three should stimulate MDGF release. But the
Figure 3, except zymosan (100 ,g/ml), with or without 1 M efficacy of aspirin and the inability of piroxicam to stim-
NDGA, was added at time zero, Instead of LPS. Data represent ulate MDGF release contrasted sharply with their ability
means ± SE, N = 6. or lack of ability to inhibit PGE2 production. This would
suggest additional (other than by cyclooxygenase inhibi-
tion) mechanism(s) by which indomethacin, aspirin, and
ibuprofen could stimulate MDGF release. But it re-
 mained clear that at least a product of the cyclooxygenaseI
S
pathway, namely PGE2, was inhibitory to LPS-inducedI
 MDGF release, and this represented one mechanism by
U
>. which cyclooxygenase inhibition could result in stimula-
I-.
; tion (or release from inhibition) of LPS-induced MDGF
C.) release. The ineffectiveness of BW755c with respect to
4
U. LPS-induced MDGF release may be due to its ability to
C,
0 also inhibit the lipoxygenase pathway [5], thus simulta-
neously inhibiting a pathway whose products could di-
- 10 -9 -8 - 7 -6 rectly stimulate MDGF release, as shown by the
LEUKOTRIENE [log Ml leukotriene data. These complex dose-dependent effects
Fig. 8. Effects of leukotrienes on MDGF release. Macrophages are partly the result of the lack of specificity of these
were incubated with the indicated concentrations of leuko- inhibitors at relatively high doses [5]. The stimulatory
trlene (4 = LTc4, B4 = LTB4) with or without 5 M FPL557i2 effect of acetaminophen is unexpected, and is in direct
added 15 mm prior to LTC4 addition, for 16 h. Media were then
assayed for MDGF activity. Data represent means ± SE contrast to its lack of effect on LPS-induced IL-l release
(N = 6). [17], which provides further support for the conclusion
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that MDGF is distinct from IL-i. The mechanism of this
stimulation of LPS-induced MDGF release by acetamin-
ophen remains to be elucidated.
In contrast to cyclooxygenase inhibition, the lipoxy-
genase inhibitor NDGA inhibited in a dose-dependent
manner the stimulation of MDGF release by both LPS
and zymosan. The latter stimulus caused MDGF release
only after a 6-7-h lag phase, and was associated also with
stimulation of the lipoxygenase pathway [14], in contrast
to LPS, which caused primarily the stimulation of the
cyclooxygenase pathway [14, 17]. Despite these differing
mechanisms of stimulation by these two dissimilar sub-
stances, the ability of NDGA to inhibit MDGF release
would suggest the existence of a common pathway in
macrophage activation and MDGF release which would
require a product or products of the lipoxygenase path-
way. This possibility was strengtheneed by the ability of
LTB4 and LTC4 to stimulate MDGF release directly, and
by the indication that at least the LTC4 effect may be
mediated by specific receptors on the macrophage. The
lack of effect of LTD4 and LTE4 provided support for the
specificity of such LTC4 receptors. The loss of inhibitory
effect by NDGA at 2 .5 jM may be due to loss of its
specificity at high doses, as suggested by its ability also
to inhibit cyclooxygenase activity at high doses [5]. Such
inhibition could result in decreased PGE production,
thus negating the inhibitory effects of decreased leuko-
triene production.
An important conclusion from these data is the in vivo
or physiologic significance of this modulation by arachi-
donate metabolites. This myriad of effects on MDGF
release was seen at doses which were physiologically
relevant ( < i08M) and likely to be encountered at sites
of tissue injury and inflammation. The sources of these
metabolites are both endogenous (ie, the macrophage
itself) and exogenous (eg, polymorphonuclear leuko-
cytes, platelets, endothelial cells, etc). Whether the end
result leads to increase fibroblast proliferation and fibro-
sis, or to inhibition of scar formation, would partly de-
pend on the resulting balance between the opposing
effects of cyclooxygenase versus lipoxygenase product
accumulation. These opposing effects of cyclooxygenase
versus lipoxygenase metabolites on MDGF release are
similar to effects seen with regard to other macrophage
mediators, such as IL-i [6,7, 17, 24, 25,31]. There are,
however, clear differences between mediators under cer-
tam conditions of cyclooxygenase inhibition for instance.
As noted above, despite inhibition of PGE production
by piroxicam, MDGF release was not affected, while IL-
1 release was increased significantly [17]. The mecha-
nism behind this discrepancy is unknown and, doubtless,
complex. This complexity is partly attributable to the
complex events associated in phagocytic cell activation.
Nevertheless, the potent effects of POE2 and LTC4 in
modulating MDGF release would suggest their in vivo
importance as endogenous, as well as exogenous, inhibi-
tor and stimulator, respectively, of fibroblast prolifera-
tion. Since different stimuli result in different spectra of
arachidonate metabolite released, the ultimate effect on
MDGF release will depend on the net effect of these
different metabolites, both inhibitory and stimulatory. It
would, therefore, be impossible to predict an effect
merely on the basis of quantitation of products of one
pathway. For example, LPS-stimulation is known to
cause increased PGE2 [14,17] and MDGF release, but
not or negligible LTC4 release [14, 17]. On the other
hand, zymosan causes increased release of all three me-
diators (PGE, MDGF, and LTC4) [14], albeit with dif-
ferent kinetics. On the basis of the lipoxygenase pathway
profile, one would have predicted, incorrectly, that zy-
mosan would be a more potent stimulator of MDGF
release, while LPS would be inhibitory.
The mechanism of this regulation by arachidonate me-
tabolites remains to be elucidated. This is likely to occur
at three major possible sites. First, such regulation could
occur at the level of receptor abundance or expression,
and many of the stimuli for phagocytic cell activation are
receptor mediated [15]. Second, arachidonate metabolites
have potent effects on intracellular calcium concentra-
tions [33], as well as other intracellular messengers as-
sociated with cell activation [12]. These are bound to
impact on MDGF and other mediator release. Finally,
there is evidence that LPS stimulation results in increased
transcription of certain polypeptide mediator genes, such
as tumor necrosis factor [2]. However, similar studies on
how arachidonate metabolites would regulate MDGF
gene transcription must await the availability of specific
cDNA probes for this mediator.
The susceptibility of MDGF release to inhibition by
lipoxygenase inhibitors and POE2 suggests new strategies
for the development of therapeutic agents to combat un-
desirable fibrosis, such as in hepatic cirrhosis and inter-
stitial pulmonary fibrosis. The possible efficacy of such
agents is suggested by the ability of lipoxygenase inhibi-
tors to inhibit bleomycin-induced pulmonary fibrosis [23].
This effect of NDGA is associated with the inhibition of
alveolar macrophage-derived MDGF release [23]. Thus,
the development of more specific lipoxygenase inhibitors
with less undesirable side effects may be useful for con-
trolling fibrotic diseases.
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